Last reviewed · How we verify

NCT07495865

Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2

Recruiting now Last updated 15 April 2026
What this trial tests

trial in Wrinkles in 87 participants. Currently enrolling.

Timeline
8 February 2026
Primary endpoint
12 March 2027
12 March 2027

Quick facts

Lead sponsorGlyance
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment87
Start date8 February 2026
Primary completion12 March 2027
Estimated completion12 March 2027
Sites1 location across Israel

Conditions studied

Sponsor

Glyance — full company profile →

Who can join

18 and older, any sex, with Wrinkles. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wrinkles

Currently open trials in the same condition.

Other Glyance trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07495865.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing